Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Adagloxad simolenin + OBI-821|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Adagloxad simolenin||OPT-822|OBI-822||Adagloxad simolenin is an immunotherapy comprised of Globo H hexassaccharide 1 and keyhole limpet hemocyanin, which upon treatment, results in a cytotoxic T-cell response against cells expressing Globo H, and thus, may lead to antitumor activity (NCI Drug Dictionary).|
|OBI-821||OBI-821 is a natural saponin derived from the soapbark tree, Quillaja saponaria Molina, which when combined with a vaccine may help promote a cytotoxic T-cell response against tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03562637||Phase III||Adagloxad simolenin + OBI-821||Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.||Recruiting|